Cytek Biosciences, INC

Cytek Biosciences announces departure of Chief Legal Officer and Corporate Secretary, Valerie Barnett, with a severance package and consulting agreement.

Cytek Biosciences, Inc. announced that Chief Legal Officer and Corporate Secretary Valerie Barnett will step down effective June 29, 2026.

Cytek Biosciences announces the resignation of its Senior Vice President, Global Sales and Services, effective June 5, 2026.

Cytek Biosciences reported an 8% increase in Q4 2025 revenue to $62.1 million, its highest quarterly revenue, but full-year revenue grew only 1% to $201.5 million, alongside significant declines in GAAP gross profit and Adjusted EBITDA.

Cytek Biosciences announced preliminary unaudited revenue of $62 million for Q4 2025, an 8% year-over-year increase, and $201 million for the full year 2025, signaling accelerated growth.

Cytek Biosciences reported a 2% increase in total revenue to $52.3 million for Q3 2025, alongside significant declines in gross profit, net income, and Adjusted EBITDA.

Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% year-over-year increase, alongside a net loss of $18.9 million.

Cytek Biosciences reported a net loss of $5.5 million for the third quarter of 2025, driven by increased operating expenses and a decline in product revenue, despite growth in service revenue.

Cytek Biosciences reported a 5% decrease in total revenue and an increased net loss for the first six months of 2025, alongside identified material weaknesses in internal controls.

Cytek Biosciences' Q1 2025 results reveal a revenue decrease, attributed to lower product sales, while the company continues to invest in research and development and commercial infrastructure.

Cytek Biosciences' Q3 2024 results show a slight revenue increase and a return to profitability, balanced against ongoing challenges in product sales and internal control weaknesses.

Cytek Biosciences experienced a decrease in product revenue but an increase in service revenue in the second quarter of 2024, resulting in a mixed financial performance.

Cytek Biosciences reported a significant net loss of $66.5 million in 2025, a sharp increase from the previous year, despite minimal 1% revenue growth.

Cytek Biosciences announces a 4% increase in revenue for fiscal year 2024, reaching $200.5 million, while addressing material weaknesses in internal control over financial reporting.

Cytek Biosciences' 2023 annual report reveals a revenue increase but also a net loss and identifies material weaknesses in internal control over financial reporting.

Cytek Biosciences Chief Technology Officer Ming Yan reported a gift of 135,892 shares of common stock.

Director Jack Ball acquired 43,973 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

Director Glenn P. Muir was granted 55,555 restricted stock units and 29,835 stock options by Cytek Biosciences.

Director Richard Chin was granted 33,333 restricted stock units and 18,261 stock options by Cytek Biosciences.

Director Vera Imper acquired common stock through RSU vesting and received new equity grants in Cytek Biosciences.

Director Deborah J. Neff acquired 43,973 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

Cytek Biosciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, detailing director elections, executive compensation, and auditor ratification.

Cytek Biosciences, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cytek Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to elect directors, approve executive compensation, and ratify the selection of its independent accounting firm.

Cytek Biosciences, Inc. has filed a definitive proxy statement related to its upcoming shareholder meeting.

Cytek Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, executive compensation, and the ratification of its independent accounting firm.

Millennium Management LLC and affiliated entities have reported a 6.1% beneficial ownership stake in Cytek Biosciences, Inc.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 5.2% of Cytek Biosciences, Inc. common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cytek Biosciences Inc. following an internal realignment.

Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, reported a 5.3% beneficial ownership stake in Cytek Biosciences, Inc.

Brown Capital Management, LLC has filed an Amendment No. 3 to Schedule 13G, disclosing a 3.9% beneficial ownership stake in Cytek Biosciences, Inc.

The Vanguard Group has reported a 6.13% passive beneficial ownership stake in Cytek Biosciences Inc., holding 7,765,138 shares of common stock as of June 30, 2025.